Stina L. Wickstrom

Patient Area Head And Neck
Stockholm, AB, Sweden

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 24 publications

Pleiotropic effects of BET inhibition broadly boost tumor immunogenicity to CD8+ T cells.

Pleiotropic effects of BET inhibition broadly boost tumor immunogenicity to CD8+ T cells.

Journal: Oncoimmunology

Published: April 30, 2026

Epigenetic remodeling in sarcoma promotes T-cell infiltration via modulation of the Hippo pathway.

Epigenetic remodeling in sarcoma promotes T-cell infiltration via modulation of the Hippo pathway.

Journal: Journal for immunotherapy of cancer

Published: March 09, 2026

SWE-NEO: Swedish NEO-adjuvant trial comparing anti-PD-1 monotherapy to combined anti-CTLA-4/anti-PD-1 blockade in resectable stage III melanoma: study protocol for a phase III open-label multi-centre trial.

SWE-NEO: Swedish NEO-adjuvant trial comparing anti-PD-1 monotherapy to combined anti-CTLA-4/anti-PD-1 blockade in resectable stage III melanoma: study protocol for a phase III open-label multi-centre trial.

Journal: Acta oncologica (Stockholm, Sweden)

Published: December 17, 2025

BET inhibition synergizes with RLR signaling to enhance tumor immunogenicity and T cell recognition.

BET inhibition synergizes with RLR signaling to enhance tumor immunogenicity and T cell recognition.

Journal: Cancer immunology research

Published: June 26, 2025

Reactive oxygen species: Janus-faced molecules in the era of modern cancer therapy.

Reactive oxygen species: Janus-faced molecules in the era of modern cancer therapy.

Journal: Journal for immunotherapy of cancer

Published: November 11, 2024

Tumor-associated NK cells drive MDSC-mediated tumor immune tolerance through the IL-6/STAT3 axis.

Tumor-associated NK cells drive MDSC-mediated tumor immune tolerance through the IL-6/STAT3 axis.

Journal: Science translational medicine

Published: May 15, 2024

NK cells and solid tumors: therapeutic potential and persisting obstacles.

NK cells and solid tumors: therapeutic potential and persisting obstacles.

Journal: Molecular cancer

Published: August 19, 2022

Trogocytosis and fratricide killing impede MSLN-directed CAR T cell functionality.

Trogocytosis and fratricide killing impede MSLN-directed CAR T cell functionality.

Journal: Oncoimmunology

Published: July 28, 2022

Precision radiation of immune checkpoint therapy resistant melanoma metastases (PROMMEL study): study protocol for a phase II open-label multicenter trial.

Precision radiation of immune checkpoint therapy resistant melanoma metastases (PROMMEL study): study protocol for a phase II open-label multicenter trial.

Journal: Acta oncologica (Stockholm, Sweden)

Published: May 31, 2022

Targeting of Nrf2 improves antitumoral responses by human NK cells, TIL and CAR T cells during oxidative stress.

Targeting of Nrf2 improves antitumoral responses by human NK cells, TIL and CAR T cells during oxidative stress.

Journal: Journal for immunotherapy of cancer

Published: May 09, 2022

Generation of Tumor-Specific Cytotoxic T Cells From Blood via In Vitro Expansion Using Autologous Dendritic Cells Pulsed With Neoantigen-Coupled Microbeads.

Generation of Tumor-Specific Cytotoxic T Cells From Blood via In Vitro Expansion Using Autologous Dendritic Cells Pulsed With Neoantigen-Coupled Microbeads.

Journal: Frontiers in oncology

Published: January 31, 2022

MHC Class I-Dependent Shaping of the NK Cell Ly49 Receptor Repertoire Takes Place Early during Maturation in the Bone Marrow.

MHC Class I-Dependent Shaping of the NK Cell Ly49 Receptor Repertoire Takes Place Early during Maturation in the Bone Marrow.

Journal: Journal of immunology (Baltimore, Md. : 1950)

Published: August 06, 2021

Showing 1-12 of 24

Last Updated: 09/26/2026